8-K current report · filed Oct 19, 2026

COLLEGIUM PHARMACEUTICAL, INC (COLL) 8-K Current Report: October 19, 2026

Item 1.02COLL overview

Short answer

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). $17 million payment settles all disputes with Grünenthal, including Nucynta patent litigation.

COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.02 · Termination of a Material Definitive Agreement

  • $17 million payment settles all disputes with Grünenthal, including Nucynta patent litigation
  • Grünenthal License terminated, eliminating future royalty obligations on Nucynta Products
  • Grünenthal assigned certain Nucynta-related patents to Collegium, strengthening product rights
  • Grünenthal filed to dismiss the patent infringement lawsuit, reducing litigation overhang
  • Consent Agreement remains effective except for the defined Territory termination

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings

Get the next COLL 8-K as it lands

Follow COLL for push alerts, or ask the research agent what this filing means.